Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Cowen and Company's 32nd Annual Health Care Conference on Tuesday, March 06, 2012 at 10:40 a.m. ET at the Boston Marriot Copley Place.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.


Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.

-0- 02/28/2012 /CONTACT: Kristina Lemonidis, Director, Corporate Communications, 760-603-2490; or Amy Blackley, Ph.D., Assistant Director, Corporate Communications, 760-603-2772, both of Isis Pharmaceuticals, Inc.

/Web Site: (NASDAQ-NMS:ISIS) / CO: Isis Pharmaceuticals, Inc.

ST: California IN: HEA MTC PHA BIO SU: TDS PRN -- LA60600 -- 0000 02/28/2012 12:00:00 EDT http://www.prnewswire.c